Invasive meningococcal disease (IMD) is a notifiable disease. Each report is followed by an investigation and the implementation of management measures (identification of contacts requiring a recommendation for antibiotic prophylaxis or vaccination) by the Regional Health Agency (ARS). In 2012, the number of reported IIM cases in the region was the lowest observed since 1998. However, in 2013, preliminary data show a new increase in the number of cases, notably including a resurgence of serogroup C IIM, for which a vaccine is recommended for children aged 12 months, with catch-up vaccination available up to age 24. Vaccination coverage in Lower Normandy is currently very low and does not allow for the establishment of herd immunity. Epidemiological surveillance is ongoing at both the national and regional levels to detect and prevent epidemic situations for this disease, which can progress from extremely severe to fulminant. Combined with strain surveillance by the CNR, this allows for the adaptation of general management measures as needed, particularly in the event of the establishment of a particularly invasive strain within a limited geographic area. In late 2013, the High Council for Public Health (HCSP) issued an opinion regarding the use of the Bexsero® vaccine, a vaccine against type B IIM recently authorized at the European level. The HCSP does not recommend vaccination for the general population, but only in very specific situations, for targeted populations. [...]